Cargando…

Liquiritigenin Reduces Blood Glucose Level and Bone Adverse Effects in Hyperglycemic Adult Zebrafish

Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia that induces other pathologies including diabetic retinopathy and bone disease. Adult Danio rerio (zebrafish) represents a powerful model to study both glucose and bone metabolism. Then, the aim of this study was to eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Carnovali, Marta, Luzi, Livio, Terruzzi, Ileana, Banfi, Giuseppe, Mariotti, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566992/
https://www.ncbi.nlm.nih.gov/pubmed/31075971
http://dx.doi.org/10.3390/nu11051042
_version_ 1783426973548150784
author Carnovali, Marta
Luzi, Livio
Terruzzi, Ileana
Banfi, Giuseppe
Mariotti, Massimo
author_facet Carnovali, Marta
Luzi, Livio
Terruzzi, Ileana
Banfi, Giuseppe
Mariotti, Massimo
author_sort Carnovali, Marta
collection PubMed
description Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia that induces other pathologies including diabetic retinopathy and bone disease. Adult Danio rerio (zebrafish) represents a powerful model to study both glucose and bone metabolism. Then, the aim of this study was to evaluate the effects of liquiritigenin (LTG) on blood glucose level and diabetes complications in hyperglycemic adult zebrafish. LTG is a flavonoid extracted from Glycyrrhiza glabra roots which possess important antioxidant, anti-inflammatory, and anti-diabetic properties. During four weeks of glucose treatment, LTG significantly prevented the onset of the hyperglycemia in adult zebrafish. Moreover, hyperglycemic fish showed increased advanced glycation end-products (AGEs) and parathormone levels whereas LTG completely prevented both of these metabolic alterations. Large bone-loss areas were found in the scales of glucose-treated fish whereas only small resorption lacunae were detected after glucose/LTG treatment. Biochemical and histological tartrate resistant acid phosphatase (TRAP) assays performed on explanted scales confirmed that LTG prevented the increase of osteoclastic activity in hyperglycemic fish. The osteoblastic alkaline phosphatase (ALP) activity was clearly lost in scales of glucose-treated fish whereas the co-treatment with LTG completely prevented such alteration. Gene expression analysis showed that LTG prevents the alteration in crucial bone regulatory genes. Our study confirmed that LTG is a very promising natural therapeutic approach for blood glucose lowering and to contrast the development of bone complications correlated to chronic hyperglycemia.
format Online
Article
Text
id pubmed-6566992
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65669922019-06-17 Liquiritigenin Reduces Blood Glucose Level and Bone Adverse Effects in Hyperglycemic Adult Zebrafish Carnovali, Marta Luzi, Livio Terruzzi, Ileana Banfi, Giuseppe Mariotti, Massimo Nutrients Article Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia that induces other pathologies including diabetic retinopathy and bone disease. Adult Danio rerio (zebrafish) represents a powerful model to study both glucose and bone metabolism. Then, the aim of this study was to evaluate the effects of liquiritigenin (LTG) on blood glucose level and diabetes complications in hyperglycemic adult zebrafish. LTG is a flavonoid extracted from Glycyrrhiza glabra roots which possess important antioxidant, anti-inflammatory, and anti-diabetic properties. During four weeks of glucose treatment, LTG significantly prevented the onset of the hyperglycemia in adult zebrafish. Moreover, hyperglycemic fish showed increased advanced glycation end-products (AGEs) and parathormone levels whereas LTG completely prevented both of these metabolic alterations. Large bone-loss areas were found in the scales of glucose-treated fish whereas only small resorption lacunae were detected after glucose/LTG treatment. Biochemical and histological tartrate resistant acid phosphatase (TRAP) assays performed on explanted scales confirmed that LTG prevented the increase of osteoclastic activity in hyperglycemic fish. The osteoblastic alkaline phosphatase (ALP) activity was clearly lost in scales of glucose-treated fish whereas the co-treatment with LTG completely prevented such alteration. Gene expression analysis showed that LTG prevents the alteration in crucial bone regulatory genes. Our study confirmed that LTG is a very promising natural therapeutic approach for blood glucose lowering and to contrast the development of bone complications correlated to chronic hyperglycemia. MDPI 2019-05-09 /pmc/articles/PMC6566992/ /pubmed/31075971 http://dx.doi.org/10.3390/nu11051042 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Carnovali, Marta
Luzi, Livio
Terruzzi, Ileana
Banfi, Giuseppe
Mariotti, Massimo
Liquiritigenin Reduces Blood Glucose Level and Bone Adverse Effects in Hyperglycemic Adult Zebrafish
title Liquiritigenin Reduces Blood Glucose Level and Bone Adverse Effects in Hyperglycemic Adult Zebrafish
title_full Liquiritigenin Reduces Blood Glucose Level and Bone Adverse Effects in Hyperglycemic Adult Zebrafish
title_fullStr Liquiritigenin Reduces Blood Glucose Level and Bone Adverse Effects in Hyperglycemic Adult Zebrafish
title_full_unstemmed Liquiritigenin Reduces Blood Glucose Level and Bone Adverse Effects in Hyperglycemic Adult Zebrafish
title_short Liquiritigenin Reduces Blood Glucose Level and Bone Adverse Effects in Hyperglycemic Adult Zebrafish
title_sort liquiritigenin reduces blood glucose level and bone adverse effects in hyperglycemic adult zebrafish
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566992/
https://www.ncbi.nlm.nih.gov/pubmed/31075971
http://dx.doi.org/10.3390/nu11051042
work_keys_str_mv AT carnovalimarta liquiritigeninreducesbloodglucoselevelandboneadverseeffectsinhyperglycemicadultzebrafish
AT luzilivio liquiritigeninreducesbloodglucoselevelandboneadverseeffectsinhyperglycemicadultzebrafish
AT terruzziileana liquiritigeninreducesbloodglucoselevelandboneadverseeffectsinhyperglycemicadultzebrafish
AT banfigiuseppe liquiritigeninreducesbloodglucoselevelandboneadverseeffectsinhyperglycemicadultzebrafish
AT mariottimassimo liquiritigeninreducesbloodglucoselevelandboneadverseeffectsinhyperglycemicadultzebrafish